TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04443530

Intervention type: DRUG
Intervention: Ultimaster™ Tansei™ stents
Description: Patients receiving Ultimaster™ Tansei™ stents
Study: NCT00659750

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: 200µg Ciclesonide versus Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT02616263

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder exercise
Study: NCT03199469

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Resamirigene bilparvovec
Description: Resamirigene bilparvovec is an AAV8 vector containing a functional copy of the human MTM1 (hMTM1) gene.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Resamirigene bilparvovec
Description: Resamirigene bilparvovec is an AAV8 vector containing a functional copy of the human MTM1 (hMTM1) gene.
Study: NCT02579759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PXT3003 dose 1
Description: Liquid oral solution, 5 ml twice a day, morning and evening with food
Study: NCT02130024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Description: Administered as an intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept 2.0 mg
Description: Administered as an intravitreal injection
Study: NCT02717273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard
Description: peri-operative antibiotic regimen only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: extended
Description: extended three-day course of antibiotics

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liver transplant
Description: orthotopic liver transplantation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: liver transplant
Description: orthotopic liver transplantation
Study: NCT02643030

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: hypercapnia
Description: Tidal volume (6 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 45mmHg

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: normocapnia
Description: Tidal volume (10 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 35mmHg
Study: NCT02579759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PXT3003 dose 2
Description: Liquid oral solution, 5 ml twice a day, morning and evening with food
Study: NCT02988882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle
Study: NCT03578731

Intervention type: DEVICE
Intervention: app
Description: The app is used to record the study parameters for a period of 90 days.~The following measures are used for data collection:~* Interview during regular consultation with doctor~* Web-App for gathering doctors data~* Consilium Smartphone App for gathering patient data During the course of care, the patient enters in a regular manner symptoms and treatment side effects in the Smartphone app. A continuous capture of the symptoms and treatment side effect is provided. If no entry is made within 3 days the patient is prompted to enter the data via a push message.~* Well-being through a patient rating on a visual analog scale~* Registration of symptoms and treatment side effects is done through the app~After completion of the study patients will be questioned according to:~• Usability and usefulness of the Smartphone app
Study: NCT02630316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Treprostinil
Description: Inhaled treprostinil (6 mcg/breath) administered four times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered four times daily
Study: NCT01118234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab (MabThera, F. Hoffmann-La Roche Ltd., Basel, Switzerland) 375 mg/m² every 3 months for 24 months (8 infusions) or observation
Study: NCT04314778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social incentive-based gamification
Description: At the beginning of each week, starting from postoperative day 3, the participant receives 70 points (10 points for each day that week). If the participant does not meet their daily step goal, they lose 10 points from their balance. This leverages loss aversion, which has been demonstrated to motivate behavior change more effectively with losses than gains. At the end of each week if the participant has at least 40 points, they will move up a level (levels from lowest to highest: blue, bronze, silver, gold, platinum). If not, the participant will drop a level. All participants begin at the silver level. Each week, participants get a fresh set of 70 points. Participants will receive daily feedback for the step counts, and weekly feedback for their levels. Participants in the intervention arm will be asked to identify a family member or friend to be their support sponsor. A weekly report will be sent to this person with the participant's performance (points and level).
Study: NCT03249350

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Contingency Management (CM)
Description: CM utilizes behavior modification \& cognitive behavioral strategies to target adolescent substance use. Protocol components are as follows: (a) The provider introduces CM to the youth and caregiver and engages them in the intervention; (b) The provider conducts Antecedent-Behavior-Consequence (ABC) assessments of the youth's AOD use with the youth and caregiver; (c) Based on the results of the ABC assessments, self-management planning and drug refusal skills training are implemented by the provider in collaboration with the youth and caregiver; (d) Concurrently, a point and level system contract is established with the family, which provides the youth with rewards/privileges for negative drug and alcohol tests and disincentives (e.g., extra chores) for positive tests. Until continued abstinence is achieved, components b through d are repeated; (e) The provider collaborates with the family to develop plans for sustaining long-term abstinence. Typical duration of CM is 12-16 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Contingency Management (CM+)
Description: The CM+ protocol adds the behavioral assessment and teaching system from Parent Management Training Oregon (PMTO) to standard CM to enhance parent's skill acquisition more intensely. PMTO's behavioral assessment and teaching system uses three processes to bring about changes in parenting: daily parent reports on youth behavior, anti-coercive problem-solving, and structured learning and in vivo practice of new parenting techniques.
Study: NCT04174105

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: zocaglusagene nuzaparvovec
Description: AT845 is an AAV8 vector delivering a functional copy of the human GAA gene, under the control of a muscle-specific promoter

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: zocaglusagene nuzaparvovec
Description: AT845 is an AAV8 vector delivering a functional copy of the human GAA gene, under the control of a muscle-specific promoter

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: zocaglusagene nuzaparvovec
Description: AT845 is an AAV8 vector delivering a functional copy of the human GAA gene, under the control of a muscle-specific promoter
Study: NCT02619253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Study: NCT02677896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT02806609

Intervention type: OTHER
Group type: OTHER
Intervention: Cold water immersion, with 10 degrees, for 10 minutes
Description: cold water immersion

Intervention type: OTHER
Group type: OTHER
Intervention: immersion in water at room temperature
Description: immersion in water at room temperature

Intervention type: OTHER
Group type: OTHER
Intervention: active recovery - running
Description: active recovery

Intervention type: OTHER
Group type: OTHER
Intervention: rest in the chair
Description: rest in the chair
Study: NCT03793530

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration
Description: Transforaminal lumbar interbody fusion with local bone graft and intraoperative bone marrow concentration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transforaminal lumbar interbody fusion with local bone graft
Description: Transforaminal lumbar interbody fusion with local bone graft
Study: NCT02658019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle.
Study: NCT03066895

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BabyGentleStick
Description: Experimental device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Lancing Device
Description: HMC standard of care.
Study: NCT02466386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489
Description: Participants will receive 5 mg of SPD489 capsule orally once daily in the morning and titrated in a step-wise fashion up to either 10 mg, 15 mg, 20 mg, or 30 mg until an optimal dose was reached.
Study: NCT02579759

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Liquid oral solution, 5 ml twice a day, morning and evening with food
Study: NCT00670514

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nix Individual
Description: Eight 40-minutes sessions at the local dental clinic during 4 months. Written material and counseling by a dental hygienist with special training in smoking cessation, according to a fixed program. A traditional smoking cessation program with a mixture of behavior therapy, coaching and pharmacological advises. Two questionnaires.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Fimpa dig fri
Description: One 30-minute counseling session at the local dental clinic, focusing on explaining the content of a traditional self-help program (Fimpa dig fri). The leaflet contains an 8-week program with instructions and tasks to perform. Two questionnaires.
Study: NCT00747201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Replicating Effective Programs Framework for the Bipolar Care Model
Description: Health care providers will receive adapted manuals, training, and technical assistance in the bipolar care model.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar Care Model Package Only
Description: Health care providers will receive only the adapted manuals.
Study: NCT04316195

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of the bulbocavernosus reflex
Description: According to the International Standards for Neurological Classification of Spinal Cord : The standard examination consists of the contraction of the bulbocavernous muscle following stimulation of the glans of the penis in men and of the clitoris in women.~By electromyography: The electromyography consists to stimulate the bulbocavernosus reflex with a bipolar probe apply on the glans for men, and on the clitoris in women. A surface electrode will be positioned on the right or left bulbocavernous muscle at the base of the penis (or vagina) and the anus for recording. The bulbocavernous reflex will be obtained by stimulation at a frequency of 1.5Hz and an amplitude of 14 to 47 mA.
Study: NCT01858922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABVE-PC
Description: Doxorubicin (A) 25mg/m2/day IV over 10min on Day 1 \& Day 2~Bleomycin (B) 5units/m2/day IV over 10min on Day 1 10units/m2/day IV over 10min on Day 8~Vincristine (V) 1.4mg/m2/day IV push with extravasation precautions on Day 1 \& 8 (Max dose 2.8mg)~Etoposide (E) 125mg/m2/day IV over 1hr at a concentration of \</=0.4mg/ml in NS on Day 1, 2 \& 3~Prednisone (P) 40mg/m2/day PO divided in 2 doses every day on Day 1-7 IV equivalent of methylprednisolone is acceptable~Cyclophosphamide (C) 800 mg/m2 IV over 1 hr in 200 ml/m2 NS on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABVE-PC
Description: Doxorubicin (A) 25mg/m2/day IV over 10min on Day 1 \& Day 2~Bleomycin (B) 5units/m2/day IV over 10min on Day 1 10units/m2/day IV over 10min on Day 8~Vincristine (V) 1.4mg/m2/day IV push with extravasation precautions on Day 1 \& 8 (Max dose 2.8mg)~Etoposide (E) 125mg/m2/day IV over 1hr at a concentration of \</=0.4mg/ml in NS on Day 1, 2 \& 3~Prednisone (P) 40mg/m2/day PO divided in 2 doses every day on Day 1-7 IV equivalent of methylprednisolone is acceptable~Cyclophosphamide (C) 800 mg/m2 IV over 1 hr in 200 ml/m2 NS on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DECA
Description: Dexamethasone (D):~10 mg/m2 IV over 15 minutes on Day 1 and Day 2, prior to Etoposide/Cytarabine.~Etoposide (E):~100 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with cytarabine\*~Cytarabine (A):~3000 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with etoposide\*~\*Mix together in NS at an etoposide concentration of \</=0.4 mg/ml~Dexamethasone eyedrops:~2 drops in each eye 4 times a day on Day 1, Day 2, and Day 3.~Cisplatin (C):~90 mg/m2 over 6 hours in 1000 ml/m2 NS + 10 gram/m2 mannitol on Day 1 as continuous infusion.
Study: NCT01318161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine + opioid epidurally
Description: Epidural analgesia with local anesthetic + opioid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine via PCA pump
Study: NCT00096122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study: NCT02093273

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tOPV pilot batch
Description: the tOPV vaccine is given orally

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tOPV commercial batch
Description: tOPV vaccine is given orally
Study: NCT03436732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMB-100
Description: administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMB-100
Description: administered on days 1, 3 and 5 of each 21 day cycle for up to 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-110
Description: administered on day 1 of each cycle for up to 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-110
Description: administered on day 1 of each cycle for up to 4 cycles
Study: NCT01760863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Antibiotics
Description: Oral Antibiotics will be prescribed for 3 months per recommendations of an infectious disease specialist.
Study: NCT03066180

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viveve SUI treatment
Description: Non-ablative radiofrequency treatment with surface cooling

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viveve SUI treatment
Description: Non-ablative radiofrequency treatment with surface cooling
Study: NCT01887223

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transconjunctival needling revision
Description: Surgical revision. A 25 Gauge needle was inserted under the subconjunctival space and perforate the encapsulated bled. The encapsulated bleb was ruptured with sweeping movement up and down, back and forth.
Study: NCT04579588

Intervention type: BIOLOGICAL
Intervention: Flu shot
Description: All participants will receive a single shot of the flu vaccine
Study: NCT01887223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical treatment
Description: Hypotensive eye drops are initialized one by one regarding intraocular pressure control. Nonspecific beta blocker and/or prostaglandin, followed by carbonic anhydrase inhibitors and/or selective alpha agonist.
Study: NCT00434811

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Pancreatic Islet Cells
Description: 200 ml suspension of allogenic human purified islets

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antithymocyte Globulin
Description: Participants will begin receiving ATG 2 days prior to the first islet transplant. ATG will continue to be given until Day 2 post-transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Participants will begin receiving sirolimus 2 days prior to the first islet transplant and will be given for the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: On Day 1 post-transplant, participants will receive tacrolimus, which will also be taken for the duration of the study.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept will be taken on the day of transplant and Days 3, 7, and 10 post-transplant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Islet Transplantation
Description: Transplantation of pancreatic islet cell

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Basiliximab will be used in place of ATG for the second and third transplants, if they are necessary.
Study: NCT00605657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Oral administration of valproic acid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT Scan
Description: CT scans were done before and after treating the patient with valproic acid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Sample
Description: Blood samples were collected before and after the intervention to monitor blood counts and biomarkers of ALPS
Study: NCT02447406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6094
Study: NCT02291874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Description: oral
Study: NCT01818661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-1451
Description: This is used to assess Tau burden in the brain.
Study: NCT02447406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study: NCT02956564

Intervention type: PROCEDURE
Group type: OTHER
Intervention: intrauterine intervention
Description: choose different surgeries according to different causes
Study: NCT00658073

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kidney transplantation with MSCs infusion
Description: Patients in Group A will receive the first MSCs infusion intravenously within 24 hours after kidney transplant operation , and the second infusion of MSCs will be performed two weeks later.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kidney transplantation with MSCs infusion
Description: Patients in Group A will receive the first MSCs infusion intravenously within 24 hours after kidney transplant operation , and the second infusion of MSCs will be performed two weeks later.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: kidney transplantation without MSC infusion
Description: kidney transplantation with standard immunosuppressive treatment regime
Study: NCT00661180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: Patients will receive Bay 43-9006 400 mg po twice daily in a continuous, uninterrupted schedule. Treatment will continue until there is objective evidence of disease progression, or until evidence of toxicities that are unacceptable and thought to be related to study drug, which requires discontinuation of drug, or due to withdrawn patient consent.
Study: NCT02758028

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief counseling
Description: Peer counselling is delivered based on the queries and the needs of individual clients, according to the smoking status, dependency level and the perceived barriers of each individual with the use of motivational intervention approach.~The subjects will be followed up at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month via telephone assessing their smoking status and reinforce intervention.
Study: NCT01327729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg
Description: YPEG-IFN α-2a 180mcg dose form: subcutaneous dosage : 180 mcg frequency every week or ten days or 2 weeks according to the group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg
Description: YPEG-IFN α-2a 180mcg dose form: subcutaneous dosage : 180 mcg frequency every week or ten days or 2 weeks according to the group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg
Description: YPEG-IFN α-2a 180mcg dose form: subcutaneous dosage : 180 mcg frequency every week or ten days or 2 weeks according to the group
Study: NCT01218321

Intervention type: BIOLOGICAL
Intervention: antiepileptic treatment
Description: White blood cells from peripheral blood samples
Study: NCT04437745

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YVOIRE Y-Solution 720
Description: Hyaluronic acid dermal filler
Study: NCT00692328

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa or acupuncture
Description: Comparison of subject expectancy of receiving levodopa or acupuncture.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Levodopa or acupuncture
Description: Comparison of subject expectancy of receiving levodopa or acupuncture.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Levodopa or acupuncture
Description: Comparison of subject expectancy of receiving levodopa or acupuncture.
Study: NCT01273688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eccentric training (Flex-Bar)
Description: 6x15 repetitions of supination and pronation daily over 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric training (Flex-Bar)
Description: 6x15 repetitions of supination and pronation daily over 12 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EpiHit elbow brace
Description: daily wearing of the EpiHit elbow brace
Study: NCT01062451

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril
Description: 8 mg taken orally from days 0 through 7.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan
Description: 16 mg taken orally from days 0 through 7.